|
Males
|
1.89
|
0.59–6.01
|
0.43
|
1.38
|
1.40
|
|
Females
|
0.84
|
0.2–3.55
|
1
|
|
Neonates up to 17 years old
|
0.78
|
0.2–2.98
|
1
|
1.38
|
1.64
|
|
Adult and elderly
|
2.57
|
1.04–6.36
|
0.04
|
|
Primary bloodstream infection
|
1.17
|
0.33–4.10
|
0.57
|
1.38
|
1.43
|
|
Secondary bloodstream infection
|
1.65
|
0.61–4.47
|
0.53
|
|
Length of stay > 2 days (before bloodstream infection established)
|
2.13
|
0.71–6.38
|
0.29
|
1.38
|
1.25
|
|
Length of stay ≤ than 2 days (before bloodstream infection established)
|
0.62
|
0.21–1.79
|
0.68
|
|
Infected by E. coli
|
0.96
|
0.29–3.17
|
0.95
|
1.38
|
1.47
|
|
Infected by K. pneumoniae
|
2.05
|
0.62–6.76
|
0.37
|
|
Leukocytosis
|
3.60
|
1.44–9.02
|
0.01
|
1.38
|
1.68
|
|
Non-leukocytosis
|
0.52
|
0.13–2.04
|
0.91
|
|
Neutropenia
|
0.75
|
0.11–5.18
|
1.00
|
1.38
|
1.45
|
|
Non-neutropenia
|
1.69
|
0.66–4.34
|
0.41
|
|
Underlying disease, malignancies
|
1.31
|
0.48–3.58
|
0.90
|
1.38
|
1.46
|
|
Underlying disease, non malignancies
|
1.65
|
0.48–5.74
|
0.48
|
|
Inappropriate antimicrobial prescription in definitive therapy
|
9.53
|
0.60–152.02
|
0.70
|
1.38
|
1.42
|
|
Appropriate antimicrobial prescription in definitive therapy
|
0.74
|
0.28–1.93
|
0.77
|
|
Definitive therapy using carbapenem
|
3.10
|
0.21–46.34
|
0.29
|
1.38
|
1.63
|
|
Definitive therapy using non-carbapenem
|
1.25
|
0.49–3.21
|
0.45
|
|
Empiric therapy using cephalosporin
|
1.10
|
0.39–3.10
|
1.00
|
1.40
|
1.39
|
|
Empiric therapy using non-cephalosporin
|
2.08
|
0.51–8.52
|
0.27
|
